Deborah Thomas

2.2k citations
19 papers · 1.4k · h-index 13

Impact in

  • Hematology top 1%
    • Chronic Myeloid Leukemia Treatments
    • Acute Myeloid Leukemia Research
  • Genetics top 2%
    • Chronic Lymphocytic Leukemia Research

Papers in

  • Hematology 10
    • Chronic Myeloid Leukemia Treatments 9
  • Molecular Biology 7
    • Protein Degradation and Inhibitors 2
    • Lipid Membrane Structure and Behavior 2
Co-authors
Jörge E. Cortes (12 shared papers)Hagop M. Kantarjian (11 shared papers)Susan O’Brien (10 shared papers)Farhad Ravandi (8 shared papers)Guillermo Garcia‐Manero (5 shared papers)William G. Wierda (5 shared papers)Stefan Faderl (6 shared papers)Alessandra Ferrajoli (4 shared papers)
Journals
Blood (6 papers)Cancer (4 papers)Chemical Reviews (1 paper)Journal of Clinical Oncology (1 paper)Nature Chemical Biology (1 paper)
Partner nations
United StatesPeruSlovakia

In The Last Decade

Deborah Thomas

19 papers receiving 1.3k citations

Peers

Deborah Thomas
Comparison fields: 5 of 53
  • Hematology 910
  • Genetics 361
  • Public Health, Environmental and Occupational Health 696
  • Rheumatology 310
  • Oncology 252
Replace Loredana Elia with:
Loredana Elia Italy
Nathalie Grardel France
Naval Daver United States
HM Kantarjian United States
Rebecca Garris United States
G. Borthakur United States
ER van Wering Netherlands
Maurizio Miglino Italy
Monica Kwari United States
Laurie Letvak United States
Deborah Thomas relative to Loredana Elia Italy Loredana Elia's profile →
Citations per field
00.5×2×3×3.8×
Loredana Elia · 1×
Citations per year

Countries citing papers authored by Deborah Thomas

Since Specialization
Citations

This map shows the geographic impact of Deborah Thomas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deborah Thomas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deborah Thomas more than expected).

Fields of papers citing papers by Deborah Thomas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Deborah Thomas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deborah Thomas. The network helps show where Deborah Thomas may publish in the future.

Co-authors

The 25 scholars most cited alongside Deborah Thomas, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Deborah Thomas Line = papers co-authored together Deborah Thomas links everyone, so they are left out of the graph.

All Works

19 of 19 papers shown
#Work
1
First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia
Blood ·Farhad Ravandi, Susan O’Brien, Deborah Thomas, Stefan Faderl, Dan Jones, Rebecca Garris, Samuel Dara, Jeffrey L. Jorgensen, Partow Kebriaei, Richard E. Champlin, Gautam Borthakur, Jan A. Burger, Alessandra Ferrajoli, Guillermo Garcia‐Manero, William G. Wierda, Jörge E. Cortes, Hagop M. Kantarjian
2010245
2
Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype
Blood ·Nitin Jain, Audrey L. Lamb, Susan O’Brien, Farhad Ravandi, Marina Konopleva, Elias Jabbour, Zhuang Zuo, Jeffrey L. Jorgensen, Pei Lin, Sherry Pierce, Deborah Thomas, Michael Rytting, Gautam Borthakur, Tapan M. Kadia, Jörge E. Cortes, Hagop M. Kantarjian, Joseph D. Khoury
2016223
3
Long‐term follow‐up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia
Cancer ·Farhad Ravandi, Susan O’Brien, Jörge E. Cortes, Deborah Thomas, Rebecca Garris, Stefan Faderl, Jan A. Burger, Michael Rytting, Alessandra Ferrajoli, William G. Wierda, Srđan Verstovšek, Richard E. Champlin, Partow Kebriaei, Deborah McCue, Xuelin Huang, Elias Jabbour, Guillermo Garcia‐Manero, Zeev Estrov, Hagop M. Kantarjian
2015158
4
Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome–positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses
Blood ·Hagop M. Kantarjian, Jörge E. Cortes, Susan O’Brien, Francis J. Giles, Guillermo Garcia‐Manero, Stefan Faderl, Deborah Thomas, Sima Jeha, Mary Beth Rios, Laurie Letvak, Kathy Bochinski, Ralph B. Arlinghaus, Moshe Talpaz
2002126
5
Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome
Blood ·Jörge E. Cortes, Patricia Ault, Charles Koller, Deborah Thomas, Alessandra Ferrajoli, William G. Wierda, Mary Beth Rios, Laurie Letvak, Elizabeth S. Kaled, Hagop M. Kantarjian
2003115
6
Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy
Cancer ·Alfonso Quintás‐Cardama, Hagop M. Kantarjian, Farhad Ravandi, Susan O’Brien, Deborah Thomas, Gabriela Vidal‐Senmache, William G. Wierda, Steven M. Kornblau, Jörge E. Cortes
2009112
7
Outcome of adults with acute lymphocytic leukemia after second salvage therapy
Cancer ·Susan O’Brien, Deborah Thomas, Farhad Ravandi, Stefan Faderl, Jörge E. Cortes, Gautum Borthakur, Sherry Pierce, Guillermo Garcia‐Manero, Hagop M. Kantarjian
2008111
8
Kinase domain point mutations in Philadelphia chromosome‐positive acute lymphoblastic leukemia emerge after therapy with BCR‐ABL kinase inhibitors
Cancer ·Dan Jones, Deborah Thomas, C. Cameron Yin, Susan O’Brien, Jörge E. Cortes, Elias Jabbour, Megan Breeden, Francis J. Giles, Weiqiang Zhao, Hagop M. Kantarjian
200895
9
Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome
British Journal of Haematology ·Maha El-Zimaity, Hagop M. Kantarjian, Moshe Talpaz, Susan O’Brien, Francis J. Giles, Guillermo Garcia‐Manero, Srđan Verstovšek, Deborah Thomas, Alessandra Ferrajoli, Kimberly Hayes, B. Nebiyou Bekele, Xian Zhou, Mary Beth Rios, Armand B. Glassman, Jörge E. Cortes
200474
10
BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome–positive leukemias
Blood ·Dan Jones, Rajyalakshmi Luthra, Jörge E. Cortes, Deborah Thomas, Susan O’Brien, Carlos E. Bueso‐Ramos, Seema Hai, Farhad Ravandi, M. Lima, Hagop M. Kantarjian, Jeffrey L. Jorgensen
200829
11
Targeting MYC with modular synthetic transcriptional repressors derived from bHLH DNA-binding domains
Nature Biotechnology ·Thomas E. Speltz, Z. Qiao, Colin Swenson, Xianghang Shangguan, John S. Coukos, Christopher Lee, Deborah Thomas, Jesse Santana, Sean W. Fanning, Geoffrey L. Greene, (unknown)
202220
12
Tackling Undruggable Targets with Designer Peptidomimetics and Synthetic Biologics
Chemical Reviews ·Colin Swenson, Gunasheil Mandava, Deborah Thomas, (unknown)
202416
13
Solvatochromic and pH-Sensitive Fluorescent Membrane Probes for Imaging of Live Cells
ACS Chemical Neuroscience ·Deborah Thomas, Vicente Rubio, Vijaya Iragavarapu, Esther A. Guzmán, Oliver B. Pelletier, Shahriar Alamgir, Qi Zhang, Maciej Stawikowski
202113
14
Study of cytosine arabinoside (NSC-63878) synchronization plus vincristine (NSC-67574), prednisone (NSC-10023), and L-asparaginase (NSC-109229) for remission induction in advanced acute leukemia in children.
PubMed ·Sutow Ww, Deborah Thomas, Steuber Cp, J Pullen, Tribhawan S. Vats, Bryan Jh, Morgan Sk
19766
15
Phase II Study of Combination of hyperCVAD with Dasatinib in Frontline Therapy of Patients with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL)
Blood ·Farhad Ravandi, Deborah Thomas, Hagop Kantarjian, Stefan Faderl, Charles Koller, Samuel Dara, Rebecca Garris, Partow Kebriaei, Gautam Borthakur, William G. Wierda, Jan A. Burger, Jörge E. Cortes, Susan O’Brien
20085
16
Direct inhibition of tumor hypoxia response with synthetic transcriptional repressors
Nature Chemical Biology ·Z. Qiao, Long C. Nguyen, Dongbo Yang, Christopher Dann, Deborah Thomas, Madeline Henn, Andrea Valdespino, Colin Swenson, Scott A. Oakes, Marsha Rich Rosner, (unknown)
20244
17
Phase II Study of Nelarabine With Hyper-CVAD in Patients With Previously Untreated T cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (LL)
Clinical Lymphoma Myeloma & Leukemia ·Preetesh Jain, Hagop M. Kantarjian, Deborah Thomas, Farhad Ravandi, Tapan M. Kadia, Jan A. Burger, Gautam Borthakur, Jörge E. Cortes, Naval Daver, Elias Jabbour, Charles Koller, Marina Konopleva, Naveen Pemmaraju, Mary Ann Kelly, Rebecca Garris, Susan O’Brien, Stefan Faderl
20134
18
Imatinib mesylate for the treatment of locally advanced and/or metastatic pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT).
Journal of Clinical Oncology ·Philippe A. Cassier, Silvia Stacchiotti, Hans Gelderblom, Deborah Thomas, W. van der Graaf, Beatrice Seddon, Danielle Julien, Amy J. Wagner, Jean‐Yves Blay
20103
19
Measuring Membrane Lipid Turnover with the pH-sensitive Fluorescent Lipid Analog ND6
Journal of Visualized Experiments ·Shahriar Alamgir, Oliver B. Pelletier, Deborah Thomas, Vicente Rubio, Maciej Stawikowski, Qi Zhang
20211

About Deborah Thomas

Deborah Thomas is a scholar working on Hematology, Molecular Biology, Public Health, Environmental and Occupational Health, Rheumatology and Genetics, having authored 19 papers that have together received 1.4k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (9 papers), Acute Lymphoblastic Leukemia research (7 papers), Eosinophilic Disorders and Syndromes (4 papers), Childhood Cancer Survivors' Quality of Life (3 papers), Chronic Lymphocytic Leukemia Research (3 papers), Protein Degradation and Inhibitors (2 papers), Lymphoma Diagnosis and Treatment (2 papers) and Lipid Membrane Structure and Behavior (2 papers). The work is most often cited by research in Hematology (910 citations), Genetics (361 citations), Public Health, Environmental and Occupational Health (696 citations), Rheumatology (310 citations) and Oncology (252 citations). Deborah Thomas has collaborated with scholars based in United States, Peru and Slovakia. Frequent co-authors include Jörge E. Cortes, Hagop M. Kantarjian, Susan O’Brien, Farhad Ravandi, Guillermo Garcia‐Manero, William G. Wierda, Stefan Faderl, Alessandra Ferrajoli, Elias Jabbour and Jeffrey L. Jorgensen. Their work appears in journals such as Blood, Cancer, Chemical Reviews, Journal of Clinical Oncology and Nature Chemical Biology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Loredana EliaBreakdown of academic impact, for papers by Nathalie GrardelBreakdown of academic impact, for papers by Naval DaverBreakdown of academic impact, for papers by HM KantarjianBreakdown of academic impact, for papers by Rebecca GarrisBreakdown of academic impact, for papers by G. BorthakurBreakdown of academic impact, for papers by ER van WeringBreakdown of academic impact, for papers by Maurizio MiglinoBreakdown of academic impact, for papers by Monica KwariBreakdown of academic impact, for papers by Laurie Letvak